CTK Co., Ltd Overview
CTK is a Seoul-based "factory-free" cosmetics platform company. It designs, formulates, sources packaging for, outsources the manufacture of, quality-checks and ships finished colour-cosmetic and skincare products for third-party brands. Its customers are concentrated in North America and Europe. Historically CTK was an asset-light turnkey ODM intermediary. Sell-side research describes its client list as including global majors such as L'Oréal, Unilever and Estée Lauder, alongside indie brands. Since 2022 the company has repositioned around CTKCLIP, an online B2B "beauty creation" platform with low minimum order quantities aimed at indie brands. In 2025 it bought a US OTC/cosmetics manufacturing plant in Corona, California, which ended its purely factory-free model, and it added a biodegradable-plastics materials business in Canada. The result is a small-cap, export-oriented company (about 85% US and Europe revenue in 2024) in the middle of a capital-intensive transition. Revenue is recovering (+28.9% YoY in Q2 2026), but consolidated profitability is still negative on a trailing basis.
What the company does
In its own descriptions (2018 IR deck, recruitment materials, interviews), CTK presents itself as a full-service beauty provider. It covers trend research and content planning, product design, formula development, packaging engineering, marketing support, contract production, inspection and logistics, and delivers the whole package to brand owners on a turnkey basis. A long-standing differentiator in company materials is that CTK historically owned no cosmetics factory. It used selected external manufacturing capacity while keeping formulation know-how, packaging design and project management in-house. Sell-side coverage (Yuanta, February 2024) describes the model the same way: the company outsources production of finished cosmetics, exports most of it to global brands, and builds its value on planning, branding, marketing and R&D rather than on owned plants.
The company's 2024 IR book lists its principal business lines as cosmetics and cosmetic containers (packaging). DART-based summaries describe CTK as making and selling cosmetics and cosmetic containers mainly for the US, UK and EU markets, and as running CTKCLIP, a platform that provides beauty-related services (Investing.com, from company filings).
Business model and revenue model
| Revenue stream | Nature | Disclosure status |
|---|---|---|
| Turnkey finished cosmetics (ODM/OEM via outsourced production) | Product sales. CTK invoices finished goods, mostly in USD | Main revenue driver. Sits within the CTKCLIP Division segment (about 94% of Q2 2026 revenue, DART via Butler.works) |
| Cosmetic packaging/containers | Product sales of primary packaging designed by CTK | Included in the core segment. Separate split n/d |
| Re-orders from existing customers | Recurring product revenue. Product life cycles at global clients typically run 3–5+ years | Re-order share above 70% (Hana, Dec 2024). Expected to rise from 70% to 74% in 2024 (Yuanta, Feb 2024) |
| CTKCLIP platform (low-MOQ development for indie brands) | Product sales originated through the platform. No subscription model disclosed | Platform revenue share n/d |
| US OTC/cosmetics contract manufacturing (CTK OTC Laboratories / "COL") | Contract manufacturing service and product sales. Consolidated from 2025 | Company cited COL consolidation as a driver of Q2 2026 growth (Asia Economy, Aug 2026) |
| US fulfillment / 3PL (CTK USA Fulfillment Center) | Logistics services | Company cited higher North American fulfillment volumes in Q2 2026 (Asia Economy, Aug 2026). Revenue n/d |
| Biodegradable resins and finished eco-products (CTK Bio / CTK Bio Canada) | Materials and product sales | About 2% of Q2 2026 revenue (Butler.works, DART) |
| Licensing / subscription | None disclosed | — |
Value-chain position
CTK sits upstream of brand owners. It acts as an integrator between brand marketing teams and the physical supply base: formula labs, filling plants, packaging moulders and decorators. In the North American value chain, CTK now runs a vertically linked chain from development (CTKCLIP) to manufacturing (CTK OTC Laboratories) to fulfillment (CTK USA Fulfillment Center). Its US manufacturing subsidiary describes this chain in its own directory listing (GCI Magazine).
Customer types and end-markets
Global multinational beauty groups: Hana Securities (Dec 2024) names L'Oréal, Unilever and Estée Lauder as major customers.
Retailer private label: Yuanta (June 2024) reports 11 new SKUs ordered for a large US retailer's "pure beauty" private-label line.
Indie and celebrity brands: Examples include Inn Beauty Project and SerumKind (Beauty Independent directory). KTB (2019) noted US celebrity brand launches.
Korean brands seeking US entry: The 2024–2025 OTC strategy targets Korean brand owners and Korean ODM/OEM peers that need FDA-compliant OTC production in the US (company IR, Dec 2024; eToday, Mar 2025).
Non-beauty (CTK Bio): Foodservice, packaging, public authorities and hemp-product distributors for compostable resins and finished goods. Named counterparties include the Charlotte Regional Visitors Authority, Everyday Hemp Company, NLC Energy, Star Group, a Sysco vendor registration and Blue Bottle Korea.
End-markets served are colour cosmetics (sell-side notes stress CTK's strength in make-up versus Korean ODM peers), skincare, suncare/OTC drug-cosmetics (sunscreen, acne care, skin protectants, sanitisers), and compostable packaging and consumer goods.
Independent characterisation
CTK is best understood as a project-based, North America-centric cosmetics supply-chain integrator. The original model was asset-light, cash-generative and dividend-paying: FY2017 operating margin was 21.6% (ETF Shopping, DART). It then went through a prolonged margin collapse (FY2020–FY2022) and has since tried three reinventions at once: an online platform for indie brands, a US owned-plant OTC strategy, and a biodegradable-materials venture. Revenue has stabilised at KRW 84–89bn a year in FY2023–FY2025. This is well below the KRW 110–124bn reached in FY2017–FY2021, and operating profitability has not yet returned on an annual basis. The 2025 acquisition moved the company from net-cash, low-leverage to a balance sheet with liabilities of KRW 110.5bn (FY2025), compared with KRW 34.7bn a year earlier.
Strategy
Stated strategic themes (company and IR, paraphrased)
-
The CTKCLIP platform as the core growth engine. Create new brands on the platform while keeping re-orders from global clients (CEO, Asia Economy, Aug 2024). Plans have also been stated to add 3PL logistics, OBM design and retail solutions to the platform (Premium Beauty News).
-
A North American one-stop chain for Korean beauty. Combine CTKCLIP development, COL manufacturing and US fulfillment into a single route to the US market for Korean brands and ODM peers. A VP interview (TheVC news feed) framed this as going beyond the "factory-free ODM" model.
-
US OTC leadership. Use the FDA-audited Corona plant to address MoCRA tightening and the high FDA import-refusal rate for Korean sunscreens. Target: USD 30m+ in incremental annual revenue by 2027 (eToday, Mar 2025).
-
Eco-materials. Scale CTK Bio's compostable resins as single-use plastic bans (Canada SUPPR, Korea's de-plastic roadmap) create demand.
-
Shareholder returns. Keep paying dividends (ten consecutive years). Use a differential dividend that favours minority holders and qualify as a "high-dividend company" for separate dividend taxation (Finance Scope, Apr 2026).
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Detail | Status |
|---|---|---|---|
| US OTC plant acquisition (COL) | Announced Dec 2024; closed Mar 2025 | About KRW 27.9bn; funded by a capital injection into CTK USA Holdings plus a CB | Full operation from Q4 2025. Utilisation improvement is a H2 2026 priority |
| IR Day | 13 Dec 2024 | Strategy presentation to 27 institutions | Completed |
| North America OTC Strategic TF | Mar 2025 | Sales push for suncare, basic OTC and colour OTC; R&D and capacity-sharing with Korean ODM/OEMs | Ongoing |
| CTK Bio – Everyday Hemp partnership | Jun 2025 | Hemp-based compostable straws (1m/month) and co-development | Ongoing |
| CTK Bio SUPPR compliance platform | Aug 2025 | Materials, finished goods and manufacturing integration for Canada | Ongoing |
| CTK Bio long-term supply | 2,025 | USD 3m per year | Ongoing |
| Cost efficiency / turnaround | 2,026 | Management credited cost efficiency for the Q2 2026 swing to operating profit | In progress |
| Differential dividend | Feb–Apr 2026 | KRW 110 general / KRW 60 largest shareholder | Paid 16 Apr 2026 |
| CTK Bio public-sector demonstration | Sep 2026 | Free resin for 160,000 municipal waste bags (Yongsan-gu) | Completed |
Medium-term targets and guidance
| Target | Value | Source | Outcome |
|---|---|---|---|
| 2024 revenue growth | +15–20% YoY | Yuanta (Jun 2024) | Missed (−6.0%) |
| 2024 operating margin | 7–8% | Yuanta (Jun 2024) | Missed (0.2%) |
| CTK Bio Canada 2024 revenue | USD 3m at break-even | Yuanta (Jun 2024) | — |
| 2025 revenue / OP | KRW 117.3bn / KRW 12.4bn | Hana (Dec 2024, citing company) | Missed (KRW 89.2bn / −KRW 5.7bn) |
| OTC incremental revenue | USD 30m+ per year by 2027 | eToday (Mar 2025) | Pending |
| H2 2026 | Continued improvement from ODM growth, fulfillment stabilisation and better COL utilisation (qualitative) | Asia Economy (Aug 2026) | Pending |
ESG and sustainability commitments: no quantified corporate emissions or sustainability targets were found. Sustainability is expressed mainly through CTK Bio's product strategy.
Products & Services
CTK does not publish a public price list or SKU catalogue. The table below lists every offering identified in public materials. Pricing is not publicly disclosed for any line.
Core cosmetics platform (CTKCLIP Division)
| Offering | Description / capabilities | Target customer | Launch / latest | Flagship examples |
|---|---|---|---|---|
| Turnkey full-service development | Trend research, product concept, formula, packaging, decoration, marketing support, outsourced filling, QC and logistics in one package | Global brands, retailers, indie brands | Since 2001 | Re-order programmes with global brands (L'Oréal, Unilever, Estée Lauder per Hana, Dec 2024) |
| Colour cosmetics | Make-up formulas and packages. Sell-side notes highlight colour as CTK's competitive edge over Korean ODM peers | Global and indie colour brands | Ongoing | — |
| Skincare | Turnkey skincare formulas and packaging | Brands, retailers | Ongoing | SerumKind (turnkey formulation and packaging, 2019–present per Beauty Independent) |
| Primary and secondary packaging | Innovative containers, decoration, customisation; company claims many award-winning packages | Brands | Since 1979 roots | "Mix Creative" packaging project (2019, Beauty Independent) |
| Retailer private label | Development of private-label lines for US retail | Mass and prestige retailers | 2,024 | 11 SKUs for a large US retailer's pure-beauty PB line (Yuanta, Jun 2024) |
| Vegan / cruelty-free production | Capability listed in company directory profile | Clean-beauty brands | — | — |
| CTKCLIP.com | Online B2B platform that matches curated formulas, packaging and raw materials to client briefs within a few clicks. Supported by in-house chemists ("CTK INOLAB") and packaging engineers. MOQ from 1,000 units | Indie brands, creators, start-ups, Korean brands | Launched Jun 2022 | 36,000+ partners (Dec 2024 IR Day); 46,000 clients within about 2 years of launch (ValueFinder, Jul 2025) |
| OTC cosmetics development service | Development of FDA-compliant OTC products (suncare, acne care) | North American brands | Launched mid-2024 | — |
| Own / incubated brands | SerumKind was described as an own brand entering the largest US home-shopping channel (2021) | Consumers (via partners) | 2,021 | SerumKind |
US manufacturing — CTK OTC Laboratories (COL)
| Offering | Description | Capacity / certifications |
|---|---|---|
| OTC manufacturing | Sunscreen, acne care, skin protectants and sanitisers under FDA OTC monograph rules | FDA-registered, FDA cGMP, ISO 22716. 40,000 sq ft plant plus 30,000 sq ft adjacent warehouse (GCI Magazine listing) |
| Personal care and colour cosmetics | Custom formulation, automated filling and packaging | Same facility |
| Private label / contract manufacturing | Bath and body, colour cosmetics, fragrance, oral care, suncare | Same facility |
| OTC solutions for Korean ODM/OEMs | Contract OTC production and regulatory pathway for Korean peers' US-bound products | Strategic TF launched Mar 2025 (eToday) |
Logistics and e-commerce
| Offering | Description | Status |
|---|---|---|
| CTK USA Fulfillment Center | US 3PL / e-commerce fulfillment linked to CTKCLIP and COL. A collaboration with ShipBob was reported in 2021 | Volumes rising in Q2 2026 (Asia Economy, Aug 2026) |
| PopinBorder (CTK eVision) | Cross-border bridge that links overseas suppliers (e.g., iHerb) to Korean marketplaces | Launched early 2021. Current status n/d |
Eco-friendly Materials (CTK Bio / CTK Bio Canada)
| Offering | Description | Certifications / customers |
|---|---|---|
| Compostable resins (PBAT-PHA compounds, masterbatch) | Proprietary compounding of compostable and recyclable resins without PLA or virgin plastic; inputs include upcycled hemp, lignin, sawdust and agave | TÜV Austria OK compost HOME, US FDA, Health Canada, SGS, RespirTek, KOTITI (Asia Economy, Apr 2024; FN News, Jun 2025) |
| "Earth Edition" film | Compostable stretch/pallet film | NLC Energy (2023) |
| Compostable paper coatings | Paper laminated with proprietary compostable coating | Canada SUPPR compliance offering (Aug 2025) |
| Finished foodservice goods | Cups, cutlery, straws | Charlotte Regional Visitors Authority (2024); Everyday Hemp Company (1m straws/month, 2025) |
| Cosmetic secondary packaging and waste bags | Biodegradable cartons and waste bags | Taesung Industry MOU for biodegradable cosmetic containers (Cosmorning; date not confirmed); Yongsan-gu bag programme (Sep 2026) |
| Long-term supply | USD 3m/year long-term supply contract signed in 2025 (counterparty n/d) | Finance Scope (Apr 2026) |
Financial Narrative
All figures are consolidated K-IFRS, KRW bn, fiscal years ending 31 December. Primary source: DART annual reports as compiled by ETF Shopping (etfshopping.com/stock/260930). Supplementary sources: Valueline (DART-based) and Butler.works. Blank cells mean not publicly retrieved.
Income statement
Notes. FY2021: Butler.works reports revenue of KRW 115.1bn and operating loss of KRW −14.3bn, against KRW 113.8bn / −11.9bn (ETF Shopping, Yuanta). The difference probably reflects a restatement or consolidation-scope change; both are noted. FY2025 EBITDA and pre-tax come from Valueline (DART-based). Valueline shows attributable EPS of KRW −363 against −373 (ETF Shopping). Diluted EPS n/d. FY2025 DPS: KRW 110 for general shareholders and KRW 60 for the largest shareholder.
Margins
Revenue CAGR. FY2021→FY2025: −5.9% a year. FY2022→FY2025: +8.7% a year. For long-run context, FY2017 revenue was KRW 113.0bn, so revenue in FY2025 is about 21% below its listing-year level (ETF Shopping, DART).
Long-run context (FY2017–FY2020)
Source: ETF Shopping (DART): ### Quarterly trajectory (most recent ten quarters)
Source: ETF Shopping (DART quarterly and half-year reports). Q1-25 revenue is derived from the reported +24.4% YoY growth in Q1-26. Q1-25 operating income is derived from the FY2025 total less Q2–Q4. Q3-25 net income is derived from Valueline TTM data. These three derived values are approximations.
Trailing twelve months to June 2026 (Valueline, DART-based): revenue KRW 100.5bn (the first TTM figure above KRW 100bn since FY2021), gross profit KRW 39.8bn, SG&A KRW 47.4bn, operating loss KRW 7.5bn, EBITDA −KRW 2.8bn, net loss KRW 15.0bn, interest expense KRW 4.3bn.
Balance sheet
Sources: Valueline balance sheet (FY2022–FY2025, consolidated). ETF Shopping (DART) for FY2021 liabilities and equity; FY2021 total assets are derived by adding the two. Interim 31 Mar 2026: total assets KRW 267.7bn, liabilities KRW 122.5bn, equity KRW 145.2bn, cash KRW 13.7bn (Valueline). They are in the DART notes.
Net debt. Not computable from the retrieved data. The FY2025 jump in liabilities (+KRW 75.8bn YoY), the rise in interest expense to KRW 2.4bn in FY2025 and KRW 4.3bn TTM, and derivative losses booked in finance costs all point to a meaningful borrowing and convertible-bond position. The company moved from a net-cash position to a likely net-debt position in 2025, but the exact amount is not publicly disclosed in the sources accessed.
Cash flow
Sources: ETF Shopping (DART): cash change, FY2025 FCF, dividends and buybacks. Earlier buybacks: KRW 0.2bn (FY2017), KRW 7.7bn (FY2018), KRW 2.3bn (FY2019), KRW 5.0bn (FY2020).
Ratios
ROE, ROA and asset turnover are computed on period-end equity and assets from the tables above. FY2025 ROE and ROA match ETF Shopping (−5.0%, −2.9%). ROIC, current ratio, debt/equity on financial debt, net debt/EBITDA and cash conversion cycle cannot be computed without the debt and working-capital detail, so they are not publicly disclosed in the sources accessed. Inventories were KRW 3.2–6.4bn in 2022–2025E (Kiwoom, Jul 2025), which is consistent with an asset-light model with low inventory.
Commentary: trends, inflections and drivers
Revenue. The FY2022 collapse (−39%) followed the loss of volume at key global customers. Earlier, the FY2018–FY2019 notes from KTB show heavy dependence on one customer ("I company", running at about USD 14–20m a quarter). Yuanta later wrote that 2023 sales were hit by indie-brand attrition but offset by global brands. Recovery since then has been uneven. Revenue grew 28% in FY2023, fell 6% in FY2024 as a major client deferred orders in Q1, and grew 7% in FY2025. Quarterly revenue is volatile: Q3-25 was KRW 31.1bn and Q4-25 was KRW 16.0bn. This reflects project-based ordering. The H1 2026 rebound (+24% and +29% YoY) is the strongest two-quarter run since 2021. Management credits Korean-beauty demand at the HQ ODM business, higher US fulfillment volume and the consolidation of COL.
Gross margin. Gross margin has improved structurally, from 22–33% in FY2017–FY2021 to 37.8–39.5% in FY2023–FY2025. The drivers are a higher re-order mix (Yuanta: re-orders carry higher margins) and container sales. Gross margin dipped slightly in TTM June 2026 (39.6%) as manufacturing revenue with a different cost structure was added.
Operating income. The problem sits below gross profit. SG&A rose from about KRW 33.9bn (TTM June 2025) to KRW 47.4bn (TTM June 2026), per Valueline. Within it, salaries rose from KRW 12.7bn to KRW 17.9bn and depreciation from KRW 3.7bn to KRW 8.7bn. These reflect the US plant and the larger group structure. In parent-only terms, payroll was 10.7% of parent revenue in FY2025 against 6.5% in FY2021 (ETF Shopping). The eco-materials business is also loss-making (Kiwoom).
Below the line. Finance costs of KRW 13.96bn in FY2025 (Valueline) include derivative losses (KRW 1.26bn in FY2025; KRW 6.38bn TTM June 2026), interest and FX. Together with fund valuation swings, they push net income consistently below operating income. TTM June 2026 net loss (−KRW 15.0bn) is twice the operating loss.
Guidance credibility. Management targets have repeatedly missed:
-
2024 target of 15–20% revenue growth and 7–8% operating margin (Yuanta, Jun 2024), against an actual −6% and 0.2%.
-
2025 company target of revenue KRW 117.3bn and operating profit KRW 12.4bn (Hana, Dec 2024), against an actual KRW 89.2bn and −KRW 5.7bn.
-
Kiwoom's 2025E of revenue KRW 98.3bn and operating profit KRW 2.0bn (Jul 2025) also overshot.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment (DART Label) Overview
| Segment (DART label) | What it contains | Share of revenue (Q2 2026) | Segment operating income / margin |
|---|---|---|---|
CTKCLIP Division (CTKCLIP본부) | Turnkey cosmetics and packaging for global and indie brands; CTKCLIP platform; very likely also US OTC manufacturing and fulfillment (classification not confirmed) | ~94% | — |
Eco-friendly Materials (친환경소재) | CTK Bio / CTK Bio Canada compostable and recyclable resins and finished goods | ~2% | n/d. Described as loss-making (Kiwoom, Jul 2025) |
Other (기타) | Unclassified / other activities | ~4% | — |
Segment revenue (KRW Bn)
| Segment revenue (KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total consolidated revenue | 88.9 | 83.6 | 89.2 |
Group Entities
| Entity | Country | Role | Ownership | Latest data |
|---|---|---|---|---|
CTK Co., Ltd | Korea | Listed parent; HQ; sales, R&D, packaging design | — | Parent revenue FY2025 KRW 67.9bn (ETF Shopping, DART) |
CTK USA Holdings Corporation | USA | US holding company for OTC plant and fulfillment | 100% | Total assets KRW 73.9bn; net loss KRW 1.53bn (DART FY2025 via ETF Shopping) |
CTK OTC Laboratories, LLC ("COL") | Corona, California, USA | FDA-registered OTC and cosmetics manufacturing | Indirect (via CTK USA Holdings) | 40,000 sq ft plant plus 30,000 sq ft warehouse (GCI Magazine listing) |
CTK USA Fulfillment Center | USA | 3PL / e-commerce fulfillment | Indirect | — |
CTK eVision | USA | Cross-border e-commerce (PopinBorder) | — | — |
CTK Bio Canada / CTK Bio | Surrey, BC, Canada (Korean entity also referenced) | Compostable resin compounding and finished products | Described in Korean press as a second-tier subsidiary of CTK | — |
Smilegate Aphrodite PEF | Korea | Financial investment vehicle | 60% | Total assets KRW 7.3bn |
Regent Cross-border New Technology Investment Association | Korea | Investment vehicle | 84.75% | Total assets KRW 1.1bn |
Smilegate Aphrodite Sub-One Fund | Korea | Fund | 19.05% | Total assets KRW 10.0bn |
Minority investments | Korea / Singapore / US | Colosseum Corp. 6.27%; 2022 SBI Innovation Growth Fund 2.17%; Premier IBK KDB K-Bio Vaccine Fund 1.92%; Livicon 1.79%; Muse M 1.39%; Lukla Inc. (OROS) 1.24%; Endowus Technologies 0.39% | Various | ETF Shopping (DART FY2025) |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 113.8 | 69.4 | 88.9 | 83.6 | 89.2 |
Revenue growth YoY (%) | -8.3 | -39.1 | 28.2 | -6.0 | 6.7 |
Cost of sales (KRW Bn) | 80.5 | 47.5 | 55.3 | 51.2 | 53.9 |
Gross profit (KRW Bn) | 33.3 | 21.9 | 33.6 | 32.4 | 35.3 |
Operating income (KRW Bn) | -11.9 | -15.2 | 2.7 | 0.1 | -5.7 |
EBITDA (KRW Bn) | — | — | — | — | 1.5 |
Pre-tax income (KRW Bn) | — | — | — | — | -7.1 |
Net income (KRW Bn) | -3.9 | -21.2 | 6.2 | -3.7 | -7.3 |
EPS basic (KRW) | — | — | 369 | -173 | -373 |
Dividend per share, general shareholders (KRW) | 100 | 50 | 100 | 100 | 110 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin | 29.2 | 31.5 | 37.8 | 38.8 | 39.5 |
Operating margin | -10.5 | -21.9 | 3.1 | 0.2 | -6.4 |
EBITDA margin | — | — | — | — | 1.6 |
Net margin | -3.4 | -30.5 | 7.0 | -4.5 | -8.2 |
Income Statement and Margin Analysis (%) (FY2017–FY2020)
| Metric | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|
Revenue (KRW Bn) | 113.0 | 110.5 | 116.3 | 124.2 |
Gross margin (%) | 31.3 | 22.4 | 26.9 | 33.1 |
Operating income (KRW Bn) | 24.4 | 5.2 | 4.0 | 0.5 |
Operating margin (%) | 21.6 | 4.7 | 3.4 | 0.4 |
Net income (KRW Bn) | 15.3 | 7.8 | 7.2 | -2.0 |
EPS (KRW) | 1,853 | 796 | 797 | — |
Financial Analysis
| Metric (KRW Bn) | Q1-24 | Q2-24 | Q3-24 | Q4-24 | Q1-25 | Q2-25 | Q3-25 | Q4-25 | Q1-26 | Q2-26 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 18.4 | 23.1 | 24.2 | 17.9 | 19.7 | 22.5 | 31.1 | 16.0 | 24.5 | 29.0 |
Operating income | -0.8 | 0.7 | 0.5 | -0.2 | 0.4 | 0.2 | -4.1 | -2.2 | -1.7 | 0.5 |
Net income | -0.7 | 0.4 | 0.7 | -4.1 | — | — | -4.8 | -3.7 | -4.6 | -1.9 |
Balance Sheet
| Metric (KRW Bn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets | 208.3 | 178.7 | 189.7 | 191.2 | 256.8 |
Current assets | — | 81.6 | 87.4 | 77.5 | 65.6 |
Cash and cash equivalents | — | 35.8 | 16.9 | 31.5 | 9.5 |
Short-term financial assets | — | 16.2 | 19.0 | 6.5 | 11.1 |
Total liabilities | 29.6 | 27.7 | 31.2 | 34.7 | 110.5 |
Total equity | 178.7 | 151.0 | 158.5 | 156.5 | 146.3 |
Cash Flow
| Metric (KRW Bn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net change in cash | 14.0 | -13.4 | -19.0 | 13.4 | -21.3 |
Free cash flow | — | — | — | — | -33.5 |
Dividends declared for the year | 1.8 | 0.5 | 1.5 | 1.5 | 1.7 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) | -2.2 | -14.0 | 3.9 | -2.4 | -5.0 |
ROA (%) | -1.9 | -11.9 | 3.3 | -1.9 | -2.9 |
Liabilities / equity (%) | 16.6 | 18.3 | 19.7 | 22.2 | 75.5 |
Asset turnover (x) | 0.55 | 0.39 | 0.47 | 0.44 | 0.35 |
Interest coverage, EBIT / interest (x) | — | — | — | — | -2.4 |
Dividend payout (%) | — | — | 21 | — | — |
Region (% of Revenue) Overview
| Region (% of revenue) | FY2024 | Q1-25 |
|---|---|---|
North America | — | 76.5 |
Korea (domestic) | — | 10.4 |
Europe and Asia | — | 13.1 |
US plus Europe combined | 85 | 89.6 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Last close (19 Oct 2026) | KRW 2,230 | ETF Shopping |
52-week range | KRW 2,130 – 5,110 | ETF Shopping |
1-month return | -3.7% | ETF Shopping |
6-month return | -45.4% | ETF Shopping |
1-year return | -55.3% | ETF Shopping |
3-year return | n/d (price on 23 Feb 2024 was KRW 5,160, Yuanta) | — |
Historical high-water mark | KRW 28,650 on 19 Jul 2018, market cap about KRW 302.6bn (Hankyung). The share count has since changed: about 10.6m shares implied in 2018 against 19.34m now, so prices are not directly comparable | Hankyung (Jul 2018) |
Share Price and Market Valuation
| Metric | Feb-2024 | Jun-2024 | Jul-2025 | Mar-2026 | Apr-2026 | Oct-2026 |
|---|---|---|---|---|---|---|
Share price (KRW) | 5,160 | 6,900 | 4,575 | 3,985 | 3,950 | 2,230 |
Market cap (KRW Bn) | 99.8 | 133.5 | 88.5 | — | — | 43.1 |
Valuation Multiples
| Multiple | CTK | Peer reference | Source |
|---|---|---|---|
P/E (TTM) | Not meaningful (loss-making). Valueline shows −3.0x | Cosmax ~18x, Kolmar ~15x (forward, as cited in Hana's Cosmecca note, Jul 2025) | Valueline; Hana |
P/B | 0.29–0.30x | — | ETF Shopping; Valueline |
EV/EBITDA | Not meaningful (TTM EBITDA negative) | — | — |
EV/Sales | Not computable (net debt n/d). Market cap / TTM sales ≈ 0.43x | — | Computed |
Dividend yield | 4.89% (KRW 110 / KRW 2,230) | — | ETF Shopping |
Dividend per share (KRW)
| Dividend per share (KRW) | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
General shareholders | 320 | 200 | 300 | 200 | 100 | 50 | 100 | 100 | 110 |
Total dividends (KRW Bn) | 3.2 | 1.4 | 2.1 | 0.9 | 1.8 | 0.5 | 1.5 | 1.5 | 1.7 |
Analyst Conclusions
Management guidance
Qualitative (Aug 2026): continued improvement in H2 2026, driven by HQ ODM growth, stabilisation of North American fulfillment and better COL utilisation.
Quantitative: the only standing target is USD 30m+ in incremental OTC revenue by 2027 (Mar 2025). No FY2026 revenue or OP guidance was found.
Consensus
None available (no covering analysts publishing estimates).
Bull case
-
The revenue inflection is real. H1 2026 revenue was KRW 53.5bn, up about 26% YoY, and TTM revenue passed KRW 100bn for the first time since FY2021. Q2 2026 shows operating leverage returning (OP +KRW 0.47bn).
-
Strategic scarcity of the US OTC asset. With FDA refusing 57% of Korean sunscreen imports (Hana) and US tariffs in place, an FDA-registered West Coast plant fed by a 46,000-client platform could fill quickly. Reaching even half the USD 30m target would add about 25% to revenue.
-
Valuation leaves room for error. At about 0.3x book (equity KRW 145bn against a market cap of KRW 43bn) with a 4.9% yield, a return to FY2023-level profit (KRW 2.7bn OP; KRW 6.2bn NI) could justify a material re-rating.
Bear case
-
Balance-sheet strain. FY2025 FCF was −KRW 33.5bn, cash fell to KRW 9.5bn and liabilities tripled to KRW 110.5bn. TTM interest expense of KRW 4.3bn alone exceeds FY2023's operating profit.
-
Credibility gap. Three successive targets (2024 growth and margin, 2025 KRW 117bn / KRW 12.4bn OP, Kiwoom's 2025E) missed by wide margins. Q2 2026's profit was only KRW 0.47bn and the quarter still lost KRW 1.9bn at the net level.
-
Competitive crowding. Cosmax, Kolmar and Cosmecca/Englewood are expanding US OTC with balance sheets 20–30x larger. CTK's eco-materials and investment-fund activities dilute management focus and capital.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Timing | What to watch |
|---|---|---|
| Q3 2026 results | Mid-Nov 2026 | Whether Q2's operating profit holds; COL utilisation; net loss trend |
| Contents of the Sep and Oct 2026 large-shareholding filings | Immediate | Any change in the founder's stake, pledges or CB conversions |
| FY2026 dividend decision | Feb 2027 | Ability to sustain KRW 110 DPS on negative FCF |
| FY2026 annual report | By end Mar 2027 | Timely filing; debt and CB disclosure; COL goodwill and impairment |
| OTC customer wins | Ongoing | Named Korean ODM/OEM partners; sunscreen SKUs |
| CTK Bio contracts | Ongoing | Conversion of pilots (Yongsan-gu, Everyday Hemp) into recurring revenue |
| FX (USD/KRW) | Ongoing | Revenue translation |
| US tariff and FDA policy | Ongoing | OTC monograph changes; sunscreen ingredient approvals |
Analyst verdict
CTK Co., Ltd is a special-situation turnaround in a structurally attractive niche, carried out by a sub-scale company with a weak execution record. The core franchise is real. The company has two decades of turnkey development for global beauty majors, a gross margin that has risen about ten points since FY2021 to 39.5%, and a CTKCLIP funnel that has gathered tens of thousands of indie-brand prospects. The 2025 purchase of an FDA-registered OTC plant in California is strategically coherent. It puts CTK at the junction of three trends: K-beauty's push into the US, FDA scrutiny of imported sunscreens, and tariff-driven reshoring.
The financial evidence so far is unconvincing, however. Revenue in FY2025 (KRW 89.2bn) remained about 28% below FY2020. Operating losses returned, and below the line the company is absorbing heavier interest, derivative and fund-valuation charges. In one year the balance sheet moved from conservatively financed (liabilities at 22% of equity) to meaningfully levered (76%). Cash at the end of FY2025 was under KRW 10bn, and free cash flow was −KRW 33.5bn. Management has missed its own targets by wide margins, and the late FY2024 annual report adds a governance question.
Q2 2026 is the first datapoint consistent with the bull thesis: revenue grew 29% and the operating line turned slightly positive. That alone does not prove the model. What matters over the next two to three quarters is whether COL utilisation and the OTC partner pipeline produce sustained positive EBITDA without new dilutive financing. At about 0.3x book and a near-5% yield, the market is pricing substantial distress. Stance: speculative, with high dispersion of outcomes. Investors should require evidence of two or more consecutive profitable quarters, disclosure of the debt and CB terms, and named OTC customer wins before treating the discount to book as value rather than a value trap.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / background | Age / birth year | Source |
|---|---|---|---|---|
Chung In-yong (정인용; "Ian Chung") | Founder, CEO and Representative Director; largest shareholder | Founded CTK in 2001 from a family packaging/metals business (1979 roots). Led the 2017 IPO. Based mostly in the US during 2019 growth projects (KTB) | Born 1972 | Yahoo Finance; Money Today; KTB |
Hong Chang-yoon (홍창윤) | Inside Director, overall management planning | — | Born 1960 | Yahoo Finance |
Choi Chi-ho (최치호; "Cheeho Choi") | President, Cosmetics CIC / Beauty Division | — | — | Asia Economy (Dec 2024); Yahoo Finance |
Lee Jong-ho (이종호) | Vice President, Investment & Finance (formerly head of finance and the officer responsible for the FY2021 annual report); listed as a related party holding 0.01% | — | — | Asia Economy (Dec 2024); FY2021 annual report; ETF Shopping |
Kim Yoon-tae (김윤태) | Vice President, Group Strategy | — | — | Asia Economy (Dec 2024) |
Park Jin-geun ("JK Park") | CEO, CTK Bio / CTK Bio Canada | — | — | Asia Economy; Newsis |
Daniel Shum | COO, CTK Bio | Founding team reportedly former professional athletes and fitness entrepreneurs | — | Bioplastics Magazine; Waste & Recycling Magazine |
Workforce Metrics
| Item | FY2025 | Source |
|---|---|---|
Average pay per director/auditor (6 persons) | KRW 98m | ETF Shopping (DART FY2025) |
Multiple of average employee pay | 1.7x (employee average KRW 56.24m) | ETF Shopping |
Individual pay disclosure | None. Korean rules require individual disclosure only above KRW 500m, and no individual is disclosed | ETF Shopping |
Major Shareholders
| Holder | Stake (%) | Date / source |
|---|---|---|
Chung In-yong (CEO) | 39.69 | FY2025 (ETF Shopping, DART) |
Park Bo-ran (related party) | 0.96 | FY2025 |
Chung Gu-ju, Chung Ye-ju, Chung Yu-ju, Chung Gu-jun, Chung Eun-suk, Chung Hee-suk (related parties) | 0.96 each | FY2025 |
Chung Yu-suk (related party) | 0.73 | FY2025 |
Lee Jong-ho (related party) | 0.01 | FY2025 |
Largest shareholder plus related parties | 47.12 | FY2025 (49.41% at FY2021; 47.72% FY2022; 47.71% FY2023; 47.12% FY2024) |
Employee Stock Ownership Association | 2.05 | Investing.com shareholder table (date n/d) |
Treasury shares | 2.57 | Butler.works |
Minority shareholders (10,678 holders) | 39.27 | FY2025 (ETF Shopping) |
Foreign ownership | 1.6 | Kiwoom (Jul 2025) |
Institutional top 10 holders | — | Butler.works |
“—” = not publicly disclosed.
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Scale / latest data | Positioning vs CTK |
|---|---|---|---|
Cosmax (KOSPI) | Cosmetics ODM (global #1 by its own claim); US plant | FY2025 revenue KRW 2,398.8bn (+10.7%); OP KRW 195.8bn; US subsidiary revenue KRW 132.6bn (Dealsite, Feb 2026) | About 27x CTK's revenue. Owns plants; strong in Asia |
Kolmar Korea (KOSPI) | Cosmetics and pharma ODM; Kolmar USA plants | FY2025 revenue KRW 2,722.4bn; OP KRW 239.6bn, including HK inno.N (Kuki News, Feb 2026). FY2024 US subsidiary revenue KRW 57.9bn (+55%) | Diversified. Expanding US suncare and OTC directly |
Cosmecca Korea (KOSDAQ) / Englewood Lab (US) | ODM; US OTC and suncare via Englewood Lab | FY2024 OP KRW 60.4bn. 2025 forecast revenue ~KRW 550bn, OP ~KRW 68bn (analyst estimates). US OTC SKU growth in 2H25 | Closest analogue for the "Korean ODM with US OTC plant" thesis |
Englewood Lab (KOSDAQ) | US-based OTC/skincare ODM | FY2024 OP KRW 18.8bn (CosinKorea) | Direct US OTC competitor |
C&C International (KOSDAQ) | Colour-cosmetics ODM (lip, eye) | FY2024 OP KRW 29.0bn (CosinKorea); 2020 revenue KRW 89.6bn | Direct competitor in colour, CTK's strength |
Intercos Korea / Intercos (Italy) | Global colour-cosmetics ODM | Intercos Korea FY2024 OP KRW 23.0bn (CosinKorea). Group figures n/d | Global colour leader |
Yonwoo (KOSDAQ) | Cosmetic packaging | — | Packaging overlap (TheVC lists as a similar company) |
The Codi (KOSDAQ) | Cosmetics ODM/OEM | — | Small-cap peer (TheVC lists as similar) |
Cosnine | Cosmetics ODM | — | Peer (TheVC) |
Sunjin Beauty Science | Raw materials; OTC ambitions | — | OTC-adjacent (Metro Seoul, Dec 2024) |
PLA and compostable-resin suppliers (various) | CTK Bio materials | — | CTK Bio positions against PLA |
Peer Comparison FY2025
| Metric | CTK | Cosmax | Kolmar Korea |
|---|---|---|---|
Revenue FY2025 (KRW Bn) | 89.2 | 2,398.8 | 2,722.4 |
Revenue growth FY2025 (%) | 6.7 | 10.7 | — |
Operating margin FY2025 (%) | -6.4 | 8.2 | 8.8 |
Gross margin FY2025 (%) | 39.5 | — | — |
R&D intensity (% of revenue) | 0.7 | — | — |
Recent Developments
The table lists every verifiable item found. Contract-win disclosures, litigation and workforce actions were not found in public sources.*



